Title: Aarkstore - Multiple Myeloma (Kahlers Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
1Multiple Myeloma (Kahlers Disease)-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015
Category Pharmaceuticals and Healthcare
2Multiple Myeloma (Kahler's Disease)-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015, Report provides comprehensive
insights about phase III pipeline drugs and
marketed drugs across the Multiple Myeloma
(Kahler's Disease). A key objective of
DelveInsights report is to establish the
understanding for API Manufacturers for marketed
and Phase III Pipeline drugs across the different
countries and regions for the drugs falling under
Multiple Myeloma (Kahler's Disease). The Report
gives insights into patents providing thepatent
protection data and marketing exclusivity of all
the drugs across the Multiple Myeloma (Kahler's
Disease). While the leading brands, companies and
chemicals are considered thoroughly,
DelveInsights report also provides details on the
Global API Manufacturersacross the globe
coveringDrug Master FilingsofUS, Europe and API
Manufacturers in Asia specifically China and
India. The researchanalysis also presents the
global sales forecasts data till 2016.
Browse Complete Report http//www.aarkstore.com
/pharmaceuticals-healthcare/97800/multiple-myeloma
-kahlers-disease-global-api-manufacturers-marketed
-and-phase-iii-drugs-landscape-2015
3Data Sources
- The report is built using data and information
sourced from proprietary databases, primary and
secondary research and in-house analysis by
DelveInsight team of industry experts. - Secondary sources information and data has been
collected from various printable and
non-printable sources like search engines, News
websites, Government Websites, Trade Journals,
White papers, Magazines, Trade associations,
Books, Industry Portals, Industry Associations
and access to available databases. - Please noteThis report requires certain updates.
We have all the information available but require
3 business days to complete the process and
ensure it is as up-to-date as possible. Certain
sections in the report may be removed or altered
based on the availability and relevance of data
for the indicated disease. - .
-
-
4Scope
- A snapshot of the global Market therapeutics
scenario for Multiple Myeloma (Kahler's Disease). - A review of the marketed products under
prescription for Multiple Myeloma (Kahler's
Disease), regulatory information and marketing
status. - Coverage of global patent coverage and detailed
commentaries on the US patent challenges. - Graphical representation of investigational
products for patent expiry and market
exclusivities across the globe. - Product profiles for marketed products for
Multiple Myeloma (Kahler's Disease) with complete
description of mechanism of action, therapeutic
class, target, route(s) of administration and
chemical details. - Coverage of API Manufacturers for Multiple
Myeloma (Kahler's Disease) drugs in the United
States, Europe and Asian Regions with location
details. - Coverage of Regulatory filings in theUS, Europe,
and Asia specifically India and China for
Multiple Myeloma (Kahler's Disease) drugs. -
5Reasons to buy
- Evaluate the marketing status and exclusivity
details of Multiple Myeloma (Kahler's Disease)key
products to exploit opportunities for generic
drug development opportunities. - Identify and understand important and diverse
types of therapeutics under Phase III development
for Multiple Myeloma (Kahler's Disease). - Design effective counter-strategies to gain
competitive advantage by identifying the key
patent expiry details and exclusivity with
respect to Multiple Myeloma (Kahler's Disease). - API intelligence over marketed drugs forMultiple
Myeloma (Kahler's Disease)and gaining primary
intelligence over active ingredients
manufacturers across the globe. - API intelligence over leading Phase III Pipeline
drugs. - Develop and designstrategies by identifying the
API manufacturers for Phase III Pipeline products
to enhance and expand business potential and
scope.
6Table of Content
- Indication Overview
- Marketed Drugs
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing
Status - Marketed Details of Drugs by Patent Expiration
Timeline - Active Pharmaceutical Ingredient (API)
Manufacturers Assessment - API Manufacturers by United States Drug Master
File (US DMF) Status - API Manufacturers by US DMF Status (Drug
Specific) - API Manufacturers in Europe by Country
- API Manufacturers in India by State
- API Manufacturers in China by Province
- Marketed Details of Approved Drugs by Geography
- Active Pharmaceutical Ingredient (API)
Manufacturers Assessment for Phase III Pipeline
Drugs - API Manufacturers by US DMF Status (Drug
Specific)
7List of Tables
- Multiple Myeloma (Kahler's Disease) Therapeutic
Market, US, Marketed Drugs by Application Type,
2015 - Multiple Myeloma (Kahler's Disease) Therapeutic
Market, US, Marketed Drugs by Marketing Status,
2015 - Multiple Myeloma (Kahler's Disease) Therapeutic
Market, US, (Year), 2015 - Multiple Myeloma (Kahler's Disease) Marketed
Drugs, API Manufacturers by US DMF Status, 2015 - Multiple Myeloma (Kahler's Disease) Marketed
Drugs, US DMF Status Drug Specific (Number), 2015 - Multiple Myeloma (Kahler's Disease) Drugs, API
Manufacturers, Europe by Country, 2015 - Multiple Myeloma (Kahler's Disease) Drugs, API
Manufacturers, India by State, 2015 - Multiple Myeloma (Kahler's Disease) Drugs, API
Manufacturers, China by Province, 2015 -
-
-
8List of Figures
- Multiple Myeloma (Kahler's Disease) Therapeutic
Market, US, Marketed Drugs by Application Type
(), 2015 - Multiple Myeloma (Kahler's Disease) Therapeutic
Market, US, Marketed Drugs by Marketing Status
(), 2015 - Multiple Myeloma (Kahler's Disease) Therapeutic
Market, US, (Year), 2015 - Multiple Myeloma (Kahler's Disease) Marketed
Drugs, API Manufacturers by US DMF Status (),
2015 - Multiple Myeloma (Kahler's Disease) Marketed
Drugs, US DMF Status Drug Specific (Number), 2015 - Multiple Myeloma (Kahler's Disease) Drugs, API
Manufacturers, Europe by Country, 2015 - Multiple Myeloma (Kahler's Disease) Drugs, API
Manufacturers, India by State, 2015 - Multiple Myeloma (Kahler's Disease) Drugs, API
Manufacturers, China by Province, 2015
9Related reports
-
- Skin Health Spa PLC - Strategic SWOT Analysis
Review - Biovest International, Inc. (BVTIQ) - Strategic
SWOT Analysis Review - Natco Pharma Limited (NATCOPHARM) - Financial and
Strategic SWOT Analysis Review - AnGes MG, Inc. (4563) - Financial and Strategic
SWOT Analysis Review - XOMA Corporation (XOMA) - Financial and
Strategic SWOT Analysis Review - Global Epinephrine Autoinjector Market 2015-2019
- Human Growth Hormone Market in the US 2015-2019
- Global Acute Coronary Syndrome (ACS) Market
2015-2019 - Global Automated External Defibrillator Market
2015-2019 - Global Gaucher Disease Market 2015-2019
10- Multiple Myeloma (Kahlers Disease)-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015 - Published Feb 2015 100 Pages
- Multiple Myeloma (Kahler's Disease)-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015, Report provides comprehensive
insights about phase III pipeline drugs and
marketed drugs across the Multiple Myeloma
(Kahler's Disease). - Price
Format Price
PDF 2000
Site License 4000
Enterprise Wide License 6000
11Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
- You Can Visit http//www.aarkstore.com
- OR Mail us at contact_at_aarkstore.com
- Blog
- http//www.aarkstore.com/blog/
- Conference
- http//conference.aarkstore.com/
- News
- http//www.aarkstore.com/news